Skip to main content

ASH 2021 Highlights

According to results presented at the 2021 ASH Annual Meeting and Exposition, new sequencing technologies may overcome previous limitations of circulating tumor DNA (ctDNA) profiling in patients with central nervous system (CNS) lymphoma. Read More ›

The addition of isatuximab (Sarclisa) to the triplet of lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (RVd) achieved superior minimal residual disease (MRD) negativity rates versus standard therapy with RVd alone as induction treatment in transplant-eligible patients with newly diagnosed multiple myeloma, according to results of the phase 3 GMMG-HD7 clinical trial presented at the 2021 ASH Annual Meeting and Exposition. Read More ›

Patients with acute myeloid leukemia (AML) harboring IDH1 mutations who were not suitable for intensive chemotherapy had improved event-free survival and overall survival (OS) with the combination of ivosidenib (Tibsovo) plus azacitidine (Onureg) versus azacitidine plus placebo, according to results of the phase 3 AGILE trial presented at the 2021 ASH Annual Meeting and Exposition. Read More ›

The antibody–drug conjugate polatuzumab vedotin-piiq (Polivy) added to R-CHP (rituximab [Rituxan], cyclophosphamide, doxorubicin, and prednisone) achieved a 27% reduction in the risk for progression or death compared with the standard regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) as first-line therapy for patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL). Read More ›

Treatment with time-limited venetoclax (Venclexta)-based combination regimens resulted in superior rates of undetectable minimal residual disease (uMRD) in the peripheral blood at 15 months compared with chemoimmunotherapy (CIT) in fit patients with chronic lymphocytic leukemia (CLL), according to findings from the GAIA (CLL13) clinical trial. Read More ›

The results from 2 phase 3 clinical trials highlighted the superiority of CAR T-cell therapies over current standard of care (SOC) when used earlier in the course of treatment for patients with large B-cell lymphoma (LBCL). These findings were reported at the ASH 2021 Annual Meeting and Exposition. Read More ›

Results from 2 single-center studies presented at the ASH 2021 Annual Meeting and Exposition showed that nearly 1 in 6 patients with hematologic diseases had no or low antibody response after a second COVID-19 vaccination, but that the mRNA 1273 COVID-19 vaccine induced a strong antibody response in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Read More ›

Treatment with the investigational agent mosunetuzu­mab (RG7828) as monotherapy induced deep remissions in patients with relapsed/refractory follicular lymphoma, according to results of a recent trial presented at the ASH 2021 Annual Meeting and Exposition. Read More ›